VAV1 and diffuse large B-cell lymphoma: Inhibiting RAC2 or its binding partner VAV1 is synergistic with ibrutinib also in DLBCL just like inhibiting STAT3 or SYK together with ibrutinib in MYD88 mutated DLBCL (89–91).